pazi o cemu vam pricam, potpuno nov pristup svemu, evo kakve vakcine sleduju i zasto ce se uvesti:
https://pubmed.ncbi.nlm.nih.gov/31279103/
Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity
Daniel Sanchez-Guzman 1, Pierre Le Guen 2, Berengere Villeret 1, Nuria Sola 1, Remi Le Borgne 3, Alice Guyard 4, Alix Kemmel 1, Bruno Crestani 2, Jean-Michel Sallenave 1, Ignacio Garcia-Verdugo 5
Affiliations Expand
PMID: 31279103 DOI: 10.1016/j.biomaterials.2019.119308
Abstract
Most of current influenza virus vaccines fail to develop a strong immunity at lung mucosae (site of viral entry) due to sub-optimal vaccination protocols (e.g. inactivated virus administered by parenteral injections). Mucosal immunity could be improved by using locally-delivered vaccines containing appropriate adjuvants. Here we show, in a mouse model, that inclusion of silver nanoparticles (AgNPs) in virus-inactivated flu vaccine resulted in reduction of viral loads and prevention of excessive lung inflammation following influenza infection. Concomitantly, AgNPs enhanced specific IgA secreting plasma cells and antibodies titers, a hallmark of successful mucosal immunity. Moreover, vaccination in the presence of AgNPs but not with gold nanoparticles, protected mice from lethal flu. Compared with other commercial adjuvants (squalene/oil-based emulsion) or silver salts, AgNPs stimulated stronger antigen specific IgA production with lower toxicity by promoting bronchus-associated lymphoid tissue (BALT) neogenesis, and acted as a bona fide mucosal adjuvant.